PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Gnosis, a Southern California-based diagnostic lab advancing women's health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for ...

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and ...